MedPath

Effect of Anticholinergic Drug On uroflowmetry

Phase 3
Conditions
Benign Prostatic Hyperplasia.
Enlarged prostate
Registration Number
IRCT20190928044913N1
Lead Sponsor
Sabzevar University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
Male
Target Recruitment
60
Inclusion Criteria

Patient Whit Benign Prostatic Hyperplasia treat with a Blaker

Exclusion Criteria

Past Mediacal History of Prostatic cancer
Age underb 50 years
Past Medical History Prostatic surgery
Past Medical History Of neurology illness
History Of Use Anticholinergic In 2 Past Week

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Q max in uroflowmetry. Timepoint: at begening and 1 month later. Method of measurement: uroflowmetri.
Secondary Outcome Measures
NameTimeMethod
rine rezidual. Timepoint: at beginnig and 1 month later. Method of measurement: sonography.;Prostate volume. Timepoint: at beginning and 1 month later. Method of measurement: sonography.
© Copyright 2025. All Rights Reserved by MedPath